Furthermore, substances targeting BRAF alterations (a combination of dabrafenib and trametinib), HER2-signaling pathways (trastuzumab deruxtecan), and alterations in the receptor tyrosine kinase RET (selpercatinib) are FDA-approved for treating solid tumors harboring corresponding alterations, including patients with advanced CCA. The gene discussed is NTRK1; the disease is cholangiocarcinoma.